


INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

10/510383

Applicant's or agent's file reference Cal 86062		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/EP 03/03784	International filing date (day/month/year) 11.04.2003	Priority date (day/month/year) 17.04.2002	
International Patent Classification (IPC) or both national classification and IPC C07C69/734			
Applicant ISAGRO RICERCA S.R.L.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 11 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 11.11.2003		Date of completion of this report 02.07.2004	
Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer Seelmann, M Telephone No. +49 89 2399-8335	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/03784**

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-43 as originally filed

Claims, Numbers

1-23 received on 27.02.2004 with letter of 26.02.2004

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/03784**

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	
	No: Claims	1-3,6-12,15-23
Inventive step (IS)	Yes: Claims	
	No: Claims	4,5,13,14
Industrial applicability (IA)	Yes: Claims	1-23
	No: Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/03784

Item V

Reasoned statement under Artikel 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1 US 5 145 980

D2 US 55 45 664

D3 EP 0 398 692 cited in the present application

V.3 Amendments

The definition provided in the amended claim 1 concerning the A parameter fulfills the requirements of article 6 PCT.

The present claim 1 was modified such that the scope has been reduced to compounds of formula (I) wherein:

$X_1, X_5 = \text{H}; X_2, X_4 = \text{Hal}; X_3 = \text{R};$

or $X_1, X_4 = \text{H}; X_3, X_5 = \text{Hal}; X_2 = \text{R};$

with $Z = \text{CH}$ or N when $Y = \text{OCH}_3$ or $Z = \text{N}$ when $Y = \text{NHCH}_3$.

These amendments correspond to the exclusion of the following originally disclosed possibilities:

1/ $X_1 = \text{Hal}$ or R

2/ $X_2 = \text{H}$

3/ $X_1, X_3 = \text{H}; X_2 = \text{R}$

4/ $X_1 = \text{H}; X_2, X_4, X_5 = \text{Hal}$

5/ $Z = \text{CH}$ when $Y = \text{NHCH}_3$.

The novelty-destroying compounds known from **D1** cover $X_1, X_5 = \text{Cl, F, Br}; X_3 = \text{Me}$ or $X_3, X_5 = \text{Cl, F, Br}; X_1 = \text{R}$ for the same activity as fungicides (*i.e.* disclaimer not allowable). The application as originally filed disclosed $X_1, X_5 = \text{H}; X_2, X_4 = \text{Hal}; X_3 = \text{R}$ in the case $n = 0$ (claim 4 or page 4).

Accordingly there seems to be no support for the proposed amendments. These latter seem to be a generalization of the examples, contravening to the requirements of article 34(2)b) PCT.

Therefore the following issues of novelty and inventive step were dealt according to the original set of claims.

V.2 Novelty

As already outlined in the description, the teaching of **D3** (claim 2) can be seen as generic in regards to the present application. The phoxymethylphenyl derivatives of general formula (I) presently claimed are already known from the prior art, for instance:

D1: compounds N°1.197 to 1.202 in table 1

Accordingly the subject-matters of claims 1-3, 6-12 and 15-23 are not novel in view of **D1**.

V.3 Inventive step

The closest state of the art for the present application is represented by **D1** disclosing structurally similar compounds which do not fall under the present application (claim 4) because of only the halogen positions on the phenyl ring: 2,6- or 2,4- (**D1**: compounds N°1.197 to 1.202) instead of 3,5-substitution in the present application (claim 4). Presently such a structural variation is alleged to lead to derivatives with the same qualitative activity/properties as those described in **D1**. In view of the experimental part and the other information as given in the description, it can be assumed that this problem has been solved for those compounds, wherein $n = 0$, $X_1 = X_5 = H$, $X_2 = X_4 = Cl$ and $X_3 = R$, *i.e.* an alkoxy, alkoxyalkyl, alkenyloxy, cycloalkylalkoxy and benzyloxy groups with possible halogen substitution or $n = 0$, $X_1 = X_4 = H$, $X_3 = X_5 = Cl$ and $X_2 = \text{alkylenoxy}$ substituted by halogen (cf. letter of applicant of 26.02.2003, table on pages 3-4).

The problem underlying the present application can, however, not be seen in the provision of further novel derivatives, because in view of the extremely close structural relationship to **D1** compounds it is considered that the man skilled in the art would regard the new compounds of this application (claim 4) as being obvious alternatives to the known compounds.

Therefore, the problem underlying the present application should be seen in the provision of new derivatives having unexpected properties over those of the closest prior art compounds (**D1**). Comparative tests were performed between compounds 1.197 and 1.200 of **D1** with those claimed in the present application (cf. letter of applicant of 26.02.2003, table on pages 3-4).

It was convincingly shown, as previously stated, that the modified position of the halogen-substitution with simultaneous presence of an oxy-moiety on the phenyl ring improves dramatically the fungicidal activity. Therefore if one has to make use of the argument that

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/03784

such a "minor" structural modifications could not be anticipated by the man skilled in the art to have such an influence on the sought activity, other more dramatic modifications as described in claim 1 cannot be considered as obvious or generalize without additional experimental evidence. Such a generalization could also lead to compounds having no effect at all. Accordingly only a reasonable generalization of the examples, not contravening to article 34(2)b) PCT, could be considered as inventive. Expressions such as heteroaryloxy or alkoxyiminoalkylidenoxy can be considered as a reasonable generalization, for instance !


The subject-matter of claim 4 and dependent claim 5 or related claims 13-14 do not therefore fulfill the requirements of Article 33(3) PCT.

Further comments:

The term "etc" is indefinite (cf. PCT Guidelines CIII-4.3a).

CLAIMS

1. Compounds having general formula (I)



(I)

- 5 wherein:
 - X₁ represents a hydrogen atom;
 - X₂ represents a halogen atom or an R group;
 - X₃ represents an R group when X₂ = halogen, or represents a halogen atom when X₂ = R;
 - 10 - X₄ represents a halogen atom when X₃ = R, or represents a hydrogen atom when X₂ = R;
 - X₅ represents a hydrogen atom when X₃ = R, or represents a halogen atom when X₂ = R;
 - R represents a C₁-C₁₂ alkoxy or alkylthio group optionally substituted by halogen atoms, cyano groups, C₁-C₆ alkoxy groups optionally halogenated, C₂-C₁₀ alkoxyalkoxy groups optionally halogenated, C₃-C₁₂ trialkyl silyl groups; a C₂-C₁₂ alkenyloxy or alkenylthio group optionally substituted by halogen atoms; a C₃-C₁₂ alkynyloxy or alkynylthio group; a linear or branched C₃-C₁₂ alkoxyimi-
- 15
- 20

noalkylidenoxy or alkoxyiminoalkylidenthio group; a C₃-C₈ cycloalkoxy group optionally substituted by halogen atoms, C₁-C₆ alkyl or haloalkyl groups; a C₄-C₁₂ cycloalkylalkoxy or cycloalkylalkylthio group optionally substituted by halogen atoms, C₁-C₆ alkyl or haloalkyl groups; an aryloxy, arylthio, heteroaryloxy, heteroarylthio, aryl-(C₁-C₆)alkoxy, aryl-(C₁-C₆)alkylthio group optionally substituted by halogen atoms, C₁-C₆ alkyl groups optionally halogenated, C₁-C₆ alkoxy groups optionally halogenated, nitro groups, cyano groups;

- A represents a halogen atom or a C₁-C₄ alkyl, haloalkyl, alkoxy, haloalkoxy group, groups A being the same or different when n is greater than or equal to 2;
- Y represents an OCH₃ group or an NHCH₃ group;
- Z represents a CH group or a nitrogen atom N when Y = OCH₃, a nitrogen atom N when Y = NHCH₃;
- n is an integer ranging from 0 to 4.

2. The compounds according to claim 1, characterized in that they are an isomeric mixture in any proportion, or the isomer E or the isomer Z of the compounds having formula (I).

3. The compounds according to claim 1, characterized in that they are the isomer E of the compounds having formula (I).

4. The compounds according to claim 1, characterized in

that X_3 represents an R group according to the above mentioned meanings, X_2 and X_4 represent a halogen atom, X_1 and X_5 represent a hydrogen atom and n is equal to 0.

5. The compounds according to claim 1, characterized in
5 that they are selected from:

- methyl (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxymethyl)phenyl]-3-methoxyacrylate;
- methyl (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxymethyl)phenyl]-2-methoxyiminoacetate;
- 10 - (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxy-methyl)phenyl]-N-methyl-2-methoxyiminoacetamide;
- methyl (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-3,5-dichlorophenoxymethyl]phenyl}-3-methoxyacrylate;
- methyl (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-
15 3,5-dichlorophenoxymethyl]phenyl}-2-methoxyiminoacetate;
- (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-3,5-dichlorophenoxymethyl]phenyl}-N-methyl-2-methoxyiminoacetamide;
- methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-
20 enyloxy)phenoxy)methyl]phenyl}-3-methoxyacrylate;
- methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-
enyloxy)phenoxy)methyl]phenyl}-2-methoxyiminoacetate;
- (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-
enyloxy)phenoxy)methyl]phenyl}-N-methyl-2-methoxyiminoacetamide;
- 25 - methyl (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-

Retyped amended claim set

trifluorobut-2-enyloxy)phenoxyethyl]phenyl}-3-methoxyacrylate;

- methyl (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-trifluorobut-2-enyloxy)phenoxyethyl]phenyl}-2-methoxyiminoacetate;

- (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-trifluorobut-2-enyloxy)phenoxyethyl]phenyl}-N-methyl-2-methoxyiminoacetamide;

- methyl (E)-2-[2-(4-cyclobutylmethoxy-3,5-dichlorophenoxyethyl]phenyl]-3-methoxyacrylate;

- methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dimethylbutoxy)phenoxyethyl]phenyl}-3-methoxyacrylate;

- methyl (E)-2-{2-[3,5-dichloro-4-(3-methylbutoxy)phenoxyethyl]phenyl}-3-methoxyacrylate;

- methyl (E)-2-[2-(4-cyclohexylmethoxy-3,5-dichlorophenoxyethyl]phenyl]-3-methoxyacrylate;


- methyl (E)-2-{2-[3,5-dichloro-4-(2,4-dichlorobenzoyloxy)phenoxyethyl]phenyl}-3-methoxyacrylate;

- methyl (E)-2-{2-[3,5-dichloro-4-(4-chlorobenzoyloxy)phenoxyethyl]phenyl}-3-methoxyacrylate.

6. The process for the preparation of the compounds having general formula (I), according to any of the claims 1-5, characterized in that it includes a condensation reaction of a compound having general formula (II) with a phenol having general formula (III), according to

the reaction scheme 1:

Scheme 1



wherein , X_1 , X_2 , X_3 , X_4 , X_5 , A , Y , Z and n have the meanings defined above, L represents a leaving group such as a chlorine atom, a bromine atom or a $R_LSO_3^-$ group wherein R_L represents a C_1 - C_6 alkyl or haloalkyl, or a phenyl optionally substituted.

7. The process according to claim 6, characterized in that the reaction is carried out in an inert organic solvent, at a temperature ranging from 0°C and the boiling temperature of the reaction mixture, possibly in the presence of an inorganic or organic base.


8. The process according to claim 7, characterized in that the solvent is selected from alcohols, ethers, esters, ketones, chlorinated hydrocarbons, aromatic hydrocarbons, aliphatic hydrocarbons, aprotic dipolar solvents.

Retyped amended claim set

9. The process according to claim 7, characterized in that the inorganic base is selected from hydrides, hydroxides, carbonates of alkaline or alkaline-earth metals.

5 10. The process according to claim 7, characterized in that the organic base is selected from pyridine, dimethylaminopyridine, aliphatic amines, cyclic amines, alcoholates of alkaline metals.

11. Use of the compounds having general formula (I)



10

(I)

wherein:

- X₁ represents a hydrogen atom;
- X₂ represents a halogen atom or an R group;
- 15 - X₃ represents an R group when X₂ = halogen, or represents a halogen atom when X₂ = R;
- X₄ represents a halogen atom when X₃ = R, or represents a hydrogen atom when X₂ = R;
- X₅ represents a hydrogen atom when X₃ = R, or represents a halogen atom when X₂ = R;
- 20

Retyped amended claim set

- R represents a C₁-C₁₂ alkoxy or alkylthio group optionally substituted by halogen atoms, cyano groups, C₁-C₆ alkoxy groups optionally halogenated, C₂-C₁₀ alkoxyalkoxy groups optionally halogenated, C₃-C₁₂ trialkyl silyl groups; a C₂-C₁₂ alkenyloxy or alkenylthio group optionally substituted by halogen atoms; a C₃-C₁₂ alkynyloxy or alkynylthio group; a linear or branched C₃-C₁₂ alkoxyiminoalkylidenoxy or alkoxyiminoalkylidenthio group; a C₃-C₈ cycloalkoxy group optionally substituted by halogen atoms, C₁-C₆ alkyl or haloalkyl groups; a C₄-C₁₂ cycloalkylalkoxy or cycloalkylalkylthio group optionally substituted by halogen atoms, C₁-C₆ alkyl or haloalkyl groups; an aryloxy, arylthio, heteroaryloxy, heteroarylthio, aryl-(C₁-C₆)alkoxy, aryl-(C₁-C₆)alkylthio group optionally substituted by halogen atoms, C₁-C₆ alkyl groups optionally halogenated, C₁-C₆ alkoxy groups optionally halogenated, nitro groups, cyano groups;
- A represents a halogen atom or a C₁-C₄ alkyl, haloalkyl, alkoxy, haloalkoxy group, groups A being the same or different when n is greater than or equal to 2;
- Y represents an OCH₃ group or an NHCH₃ group;
- Z represents a CH group or a nitrogen atom N when Y = OCH₃, a nitrogen atom N when Y = NHCH₃;
- n is an integer ranging from 0 to 4;
- as acaricides and/or insecticides and/or fungicides.

Retyped amended claim set

12. The use according to claim 11 of the isomers E of the compounds having formula (I).

13. The use according to claim 11, wherein X₃ represents an R group according to the above meanings, X₂ and X₄ represent a halogen atom, X₁ and X₅ represent a hydrogen atom and n is equal to 0.

14. The use according to claim 11, wherein the compounds of formula (I) are selected from:

- methyl (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxy)methyl]phenyl]-3-methoxyacrylate;
- methyl (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxy)methyl]phenyl]-2-methoxyiminoacetate;
- (E)-2-[2-(4-cyclopropylmethoxy-3,5-dichlorophenoxy)methyl]phenyl]-N-methyl-2-methoxyiminoacetamide;
- 15 - methyl (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-3,5-dichlorophenoxy)methyl]phenyl}-3-methoxyacrylate;
- methyl (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-3,5-dichlorophenoxy)methyl]phenyl}-2-methoxyiminoacetate;
- (E)-2-{2-[4-(2,2-dichlorocyclopropyl)methoxy-3,5-dichlorophenoxy)methyl]phenyl}-N-methyl-2-methoxyiminoacetamide;
- 20 - methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-enyloxy)phenoxy)methyl]phenyl}-3-methoxyacrylate;
- methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-enyloxy)phenoxy)methyl]phenyl}-2-methoxyiminoacetate;
- 25

Retyped amended claim set

- (E)-2-{2-[3,5-dichloro-4-(3,3-dichloroprop-2-enyloxy)-
phenoxyethyl]phenyl}-N-methyl-2-methoxyiminoacetamide;
 - methyl (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-
trifluorobut-2-enyloxy)phenoxyethyl]phenyl}-3-methoxy-
5 acrylate;
 - methyl (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-tri-
fluorobut-2-enyloxy)phenoxyethyl]phenyl}-2-methoxyimi-
noacetate;
 - (E)-2-{2-[3,5-dichloro-4-(3-chloro-4,4,4-tri-fluorobut-
10 2-enyloxy)phenoxyethyl]phenyl}-N-methyl-2-methoxyimino-
acetamide;
 - methyl (E)-2-{2-(4-cyclobutylmethoxy-3,5-dichloro-
phenoxyethyl]phenyl}-3-methoxyacrylate;
 - methyl (E)-2-{2-[3,5-dichloro-4-(3,3-dimethylbutoxy)
15 phenoxyethyl]phenyl}-3-methoxyacrylate;
 - methyl (E)-2-{2-[3,5-dichloro-4-(3-methylbutoxy) phe-
noxyethyl]phenyl}-3-methoxyacrylate;
 - methyl (E)-2-{2-(4-cyclohexylmethoxy-3,5-dichloro-
phenoxyethyl]phenyl}-3-methoxyacrylate;
 - 20 - methyl (E)-2-{2-[3,5-dichloro-4-(2,4-dichloro-
benzyloxy)phenoxyethyl]phenyl}-3-methoxyacrylate;
 - methyl (E)-2-{2-[3,5-dichloro-4-(4-chloro-
benzyloxy)phenoxyethyl]phenyl}-3-methoxyacrylate.
15. The use according to any of the claims 11-14 for the
25 control of adults, larvae and eggs of mites and insects

which are harmful in the agrarian, civil and zoo-technical field.

16. The use according to claim 15, wherein the harmful mites and/or insects are tetranychidae (*Tetranychus ur-*
5 *ticae*, *Tetranychus telarius*, *Tetranychus cinnabarinus*,
Eotetranychus carpini, *Panonychus ulmi*, *Panonychus ci-*
tri), eriophyidae (*Phytoptus avellanae*, *Eriophyes vitis*,
Eriophyes piri) tarsonemidae (*Steneotarsonemus pallidus*),
hemiptera (*Macrosiphum euphorbiae*, *Aphis fabae*, *Myzus*
10 *persicae*), lepidoptera (*Spodoptera* spp., *Heliothis* spp.,
Chilo spp., *Carpocapsa pomonella*), coleoptera (*Leptino-*
tarsa decemlineata, *Phaedon cochleariae*), diptera (*Aedes*
spp., *Culex* spp., *Musca* spp.).

17. The use according to any of the claims 11-14 for the
15 control of phytopathogenous fungi such as: *Helminthosporium* spp., *Erysiphe* spp., *Puccinia* spp., *Plasmopara viti-*
cola, *Pythium* spp., *Phytophthora* spp., *Rhynchosporium*
spp., *Septoria* spp., *Sphaerotheca fuliginea*, *Podosphaera*
leucotricha, *Pyricularia oryzae*, *Uncinula necator*, *Ventu-*
20 *ria* spp., *Botrytis cinerea*, *Fusarium* spp., *Alternaria*
spp., *Cercospora* spp.

18. The use according to any of the claims 11-14 for the
control of mites, insects and fungi which are harmful in
crops of agrarian and horticultural interest, on domestic
25 and breeding animals, in environments frequented by human

beings.

19. A method for controlling mites and/or insects and/or
phytopathogenous fungi in crops of agrarian and horticultural
interest, and/or on domestic and breeding animals,
5 and/or in environments frequented by human beings, by the
application of the compounds having general formula (I)
according to one of the claims 1-5.

20. The method according to claim 19, characterized in
that the quantity of compound to be applied varies from
10 10 g to 5 kg per hectare.

21. Acaricidal and/or insecticidal and/or fungicidal
compositions containing as active principle one or more
compounds having general formula (I) according to one of
the claims 1-5.

15 22. The compositions according to claim 21, comprising
other active principles compatible with the compounds
having general formula (I), such as other acar-
icides/insecticides, fungicides, phyto-regulators, anti-
biotics, herbicides, fertilizers.

20 23. The compositions according to claim 21, character-
ized in that the concentration of active principle ranges
from 1 to 90%, preferably from 5 to 50%.